{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T11:53:55Z","timestamp":1793361235683,"version":"4.5.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,19]],"date-time":"2022-01-19T00:00:00Z","timestamp":1642550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,19]],"date-time":"2022-01-19T00:00:00Z","timestamp":1642550400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Bonn"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Prognosis of patients with advanced extrahepatic cholangiocarcinoma (eCCA) is poor. The current standard first-line treatment is systemic chemotherapy (CT) with gemcitabine and a platinum derivate. Additionally, endobiliary radiofrequency ablation (eRFA) can be applied to treat biliary obstructions. This study aimed to evaluate the additional benefit of scheduled regular eRFA in a real-life patient cohort with advanced extrahepatic cholangiocarcinoma under standard systemic CT. All patients with irresectable eCCA treated at University Hospital Bonn between 2010 and 2020 were eligible for inclusion. Patients were stratified according to treatment: standard CT (n\u2009=\u200926) vs. combination of eRFA with standard CT (n\u2009=\u200940). Overall survival (OS), progression free survival (PFS), feasibility and toxicity were retrospectively analyzed using univariate and multivariate approaches. Combined eRFA and CT resulted in significantly longer median OS (17.3 vs. 8.6\u00a0months, p\u2009=\u20090.004) and PFS (12.9 vs. 5.7\u00a0months, p\u2009=\u20090.045) compared to the CT only group. While groups did not differ regarding age, sex, tumor stage and chemotherapy treatment regimen, mean MELD was even higher (10.1 vs. 6.7, p\u2009=\u20090.015) in the eRFA\u2009+\u2009CT group. The survival benefit of concomitant eRFA was more evident in the subgroup with locally advanced tumors. Severe hematological toxicities (CTCAE grades 3 \u2013 5) did not differ significantly between the groups. However, therapy-related cholangitis occurred more often in the combined treatment group (p\u2009=\u20090.031). Combination of eRFA and systemic CT was feasible, well-tolerated and could significantly prolong survival compared to standard CT alone. Thus, eRFA should be considered during therapeutic decision making in advanced eCCA.<\/jats:p>","DOI":"10.1038\/s41598-021-04297-2","type":"journal-article","created":{"date-parts":[[2022,1,19]],"date-time":"2022-01-19T06:02:56Z","timestamp":1642572176000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Impact of regular additional endobiliary radiofrequency ablation on survival of patients with advanced extrahepatic cholangiocarcinoma under systemic chemotherapy"],"prefix":"10.1038","volume":"12","author":[{"given":"Maria A.","family":"Gonzalez-Carmona","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"M\u00f6hring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Mahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taotao","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Bartels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farsaneh","family":"Sadeghlar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Bolch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annabelle","family":"Vogt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik J.","family":"Kaczmarek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik J.","family":"Heling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leona","family":"Dold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Nattermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittorio","family":"Branchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanno","family":"Matthaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffen","family":"Manekeller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg C.","family":"Kalff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian P.","family":"Strassburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael U.","family":"Mohr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias J.","family":"Weism\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,19]]},"reference":[{"key":"4297_CR1","doi-asserted-by":"publisher","first-page":"61","DOI":"10.21037\/cco.2016.10.09","volume":"5","author":"L Marcano-Bonilla","year":"2016","unstructured":"Marcano-Bonilla, L., Mohamed, E. A., Mounajjed, T. & Roberts, L. R. Biliary tract cancers: epidemiology, molecular pathogenesis and genetic risk associations. Chin. Clin. Oncol. 5, 61. https:\/\/doi.org\/10.21037\/cco.2016.10.09 (2016).","journal-title":"Chin. Clin. Oncol."},{"key":"4297_CR2","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1111\/liv.13954","volume":"39","author":"D Walter","year":"2019","unstructured":"Walter, D. et al. Cholangiocarcinoma in Germany: Epidemiologic trends and impact of misclassification. Liver Int. 39, 316\u2013323. https:\/\/doi.org\/10.1111\/liv.13954 (2019).","journal-title":"Liver Int."},{"key":"4297_CR3","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.3109\/00365521.2011.589472","volume":"46","author":"T von Hahn","year":"2011","unstructured":"von Hahn, T. et al. Epidemiological trends in incidence and mortality of hepatobiliary cancers in Germany. Scand. J. Gastroenterol. 46, 1092\u20131098. https:\/\/doi.org\/10.3109\/00365521.2011.589472 (2011).","journal-title":"Scand. J. Gastroenterol."},{"key":"4297_CR4","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1007\/s11894-017-0542-4","volume":"19","author":"B Doherty","year":"2017","unstructured":"Doherty, B., Nambudiri, V. E. & Palmer, W. C. Update on the diagnosis and treatment of cholangiocarcinoma. Curr. Gastroenterol. Rep. 19, 2. https:\/\/doi.org\/10.1007\/s11894-017-0542-4 (2017).","journal-title":"Curr. Gastroenterol. Rep."},{"key":"4297_CR5","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/s1470-2045(18)30915-x","volume":"20","author":"JN Primrose","year":"2019","unstructured":"Primrose, J. N. et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): A randomised, controlled, multicentre, phase 3 study. Lancet Oncol. 20, 663\u2013673. https:\/\/doi.org\/10.1016\/s1470-2045(18)30915-x (2019).","journal-title":"Lancet Oncol."},{"key":"4297_CR6","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1080\/17474124.2021.1864325","volume":"15","author":"A Rizzo","year":"2021","unstructured":"Rizzo, A. & Brandi, G. BILCAP trial and adjuvant capecitabine in resectable biliary tract cancer: Reflections on a standard of care. Expert Rev. Gastroenterol. Hepatol. 15, 483\u2013485. https:\/\/doi.org\/10.1080\/17474124.2021.1864325 (2021).","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"4297_CR7","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1097\/01.sla.0000251366.62632.d3","volume":"245","author":"ML DeOliveira","year":"2007","unstructured":"DeOliveira, M. L. et al. Cholangiocarcinoma: Thirty-one-year experience with 564 patients at a single institution. Ann. Surg. 245, 755\u2013762. https:\/\/doi.org\/10.1097\/01.sla.0000251366.62632.d3 (2007).","journal-title":"Ann. Surg."},{"key":"4297_CR8","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"J Valle","year":"2010","unstructured":"Valle, J. et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N. Engl. J. Med. 362, 1273\u20131281. https:\/\/doi.org\/10.1056\/NEJMoa0908721 (2010).","journal-title":"N. Engl. J. Med."},{"key":"4297_CR9","doi-asserted-by":"publisher","first-page":"100335","DOI":"10.1016\/j.ctarc.2021.100335","volume":"27","author":"A Rizzo","year":"2021","unstructured":"Rizzo, A. & Brandi, G. First-line chemotherapy in advanced biliary tract cancer ten years after the ABC-02 trial: \u201cand yet it moves!\u201d. Cancer Treatm. Res. Commun. 27, 100335. https:\/\/doi.org\/10.1016\/j.ctarc.2021.100335 (2021).","journal-title":"Cancer Treatm. Res. Commun."},{"key":"4297_CR10","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","volume":"21","author":"GK Abou-Alfa","year":"2020","unstructured":"Abou-Alfa, G. K. et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: A multicentre, open-label, phase 2 study. Lancet Oncol. 21, 671\u2013684. https:\/\/doi.org\/10.1016\/S1470-2045(20)30109-1 (2020).","journal-title":"Lancet Oncol."},{"key":"4297_CR11","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1007\/s00464-019-06871-2","volume":"34","author":"S O'Brien","year":"2020","unstructured":"O\u2019Brien, S. et al. Comparing the efficacy of initial percutaneous transhepatic biliary drainage and endoscopic retrograde cholangiopancreatography with stenting for relief of biliary obstruction in unresectable cholangiocarcinoma. Surg. Endosc. 34, 1186\u20131190. https:\/\/doi.org\/10.1007\/s00464-019-06871-2 (2020).","journal-title":"Surg. Endosc."},{"key":"4297_CR12","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1097\/MOG.0000000000000258","volume":"32","author":"ET Mensah","year":"2016","unstructured":"Mensah, E. T., Martin, J. & Topazian, M. Radiofrequency ablation for biliary malignancies. Curr. Opin. Gastroenterol. 32, 238\u2013243. https:\/\/doi.org\/10.1097\/MOG.0000000000000258 (2016).","journal-title":"Curr. Opin. Gastroenterol."},{"key":"4297_CR13","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1097\/MOG.0b013e32835faacc","volume":"29","author":"CA Wadsworth","year":"2013","unstructured":"Wadsworth, C. A., Westaby, D. & Khan, S. A. Endoscopic radiofrequency ablation for cholangiocarcinoma. Curr. Opin. Gastroenterol. 29, 305\u2013311. https:\/\/doi.org\/10.1097\/MOG.0b013e32835faacc (2013).","journal-title":"Curr. Opin. Gastroenterol."},{"key":"4297_CR14","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-021-08216-x","author":"GH Kim","year":"2021","unstructured":"Kim, G. H. et al. Thermal ablation in the treatment of intrahepatic cholangiocarcinoma: A systematic review and meta-analysis. Eur. Radiol. https:\/\/doi.org\/10.1007\/s00330-021-08216-x (2021).","journal-title":"Eur. Radiol."},{"key":"4297_CR15","doi-asserted-by":"publisher","first-page":"3099","DOI":"10.1007\/s10620-014-3264-6","volume":"59","author":"RZ Sharaiha","year":"2014","unstructured":"Sharaiha, R. Z. et al. Comparison of metal stenting with radiofrequency ablation versus stenting alone for treating malignant biliary strictures: Is there an added benefit?. Dig. Dis. Sci. 59, 3099\u20133102. https:\/\/doi.org\/10.1007\/s10620-014-3264-6 (2014).","journal-title":"Dig. Dis. Sci."},{"key":"4297_CR16","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1007\/s00464-013-3232-9","volume":"28","author":"W Dolak","year":"2014","unstructured":"Dolak, W. et al. Endoscopic radiofrequency ablation for malignant biliary obstruction: A nationwide retrospective study of 84 consecutive applications. Surg. Endosc. 28, 854\u2013860. https:\/\/doi.org\/10.1007\/s00464-013-3232-9 (2014).","journal-title":"Surg. Endosc."},{"key":"4297_CR17","doi-asserted-by":"publisher","first-page":"2164","DOI":"10.1007\/s10620-015-3558-3","volume":"60","author":"RZ Sharaiha","year":"2015","unstructured":"Sharaiha, R. Z. et al. Impact of radiofrequency ablation on malignant biliary strictures: results of a collaborative registry. Dig. Dis. Sci. 60, 2164\u20132169. https:\/\/doi.org\/10.1007\/s10620-015-3558-3 (2015).","journal-title":"Dig. Dis. Sci."},{"key":"4297_CR18","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1007\/s00464-015-4322-7","volume":"30","author":"A Laquiere","year":"2016","unstructured":"Laquiere, A. et al. Safety and feasibility of endoscopic biliary radiofrequency ablation treatment of extrahepatic cholangiocarcinoma. Surg. Endosc. 30, 1242\u20131248. https:\/\/doi.org\/10.1007\/s00464-015-4322-7 (2016).","journal-title":"Surg. Endosc."},{"key":"4297_CR19","doi-asserted-by":"publisher","first-page":"53911","DOI":"10.18632\/oncotarget.10116","volume":"7","author":"Y Wang","year":"2016","unstructured":"Wang, Y. et al. Percutaneous intraductal radiofrequency ablation in the management of unresectable Bismuth types III and IV hilar cholangiocarcinoma. Oncotarget 7, 53911\u201353920. https:\/\/doi.org\/10.18632\/oncotarget.10116 (2016).","journal-title":"Oncotarget"},{"key":"4297_CR20","doi-asserted-by":"publisher","first-page":"13685","DOI":"10.1038\/s41598-019-50132-0","volume":"9","author":"A Bokemeyer","year":"2019","unstructured":"Bokemeyer, A. et al. Endoscopic radiofrequency ablation prolongs survival of patients with unresectable hilar cholangiocellular carcinoma: A case-control study. Sci. Rep. 9, 13685. https:\/\/doi.org\/10.1038\/s41598-019-50132-0 (2019).","journal-title":"Sci. Rep."},{"key":"4297_CR21","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1055\/s-0043-124870","volume":"50","author":"J Yang","year":"2018","unstructured":"Yang, J. et al. Efficacy and safety of endoscopic radiofrequency ablation for unresectable extrahepatic cholangiocarcinoma: A randomized trial. Endoscopy 50, 751\u2013760. https:\/\/doi.org\/10.1055\/s-0043-124870 (2018).","journal-title":"Endoscopy"},{"key":"4297_CR22","doi-asserted-by":"publisher","first-page":"5548","DOI":"10.1038\/s41598-019-42069-1","volume":"9","author":"F Moik","year":"2019","unstructured":"Moik, F. et al. Benefit of second-line systemic chemotherapy for advanced biliary tract cancer: A propensity score analysis. Sci. Rep. 9, 5548. https:\/\/doi.org\/10.1038\/s41598-019-42069-1 (2019).","journal-title":"Sci. Rep."},{"key":"4297_CR23","doi-asserted-by":"publisher","first-page":"83","DOI":"10.4251\/wjgo.v12.i1.83","volume":"12","author":"JD Mizrahi","year":"2020","unstructured":"Mizrahi, J. D. et al. Multi-institutional retrospective analysis of FOLFIRI in patients with advanced biliary tract cancers. World J. Gastrointest. Oncol. 12, 83\u201391. https:\/\/doi.org\/10.4251\/wjgo.v12.i1.83 (2020).","journal-title":"World J. Gastrointest. Oncol."},{"key":"4297_CR24","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1111\/apt.15050","volume":"49","author":"MA Gonzalez-Carmona","year":"2019","unstructured":"Gonzalez-Carmona, M. A. et al. Combined photodynamic therapy with systemic chemotherapy for unresectable cholangiocarcinoma. Aliment Pharmacol. Ther. 49, 437\u2013447. https:\/\/doi.org\/10.1111\/apt.15050 (2019).","journal-title":"Aliment Pharmacol. Ther."},{"key":"4297_CR25","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.gie.2010.09.031","volume":"73","author":"AW Steel","year":"2011","unstructured":"Steel, A. W. et al. Endoscopically applied radiofrequency ablation appears to be safe in the treatment of malignant biliary obstruction. Gastrointest. Endosc. 73, 149\u2013153. https:\/\/doi.org\/10.1016\/j.gie.2010.09.031 (2011).","journal-title":"Gastrointest. Endosc."},{"key":"4297_CR26","doi-asserted-by":"publisher","first-page":"910897","DOI":"10.1155\/2013\/910897","volume":"2013","author":"P Figueroa-Barojas","year":"2013","unstructured":"Figueroa-Barojas, P. et al. Safety and efficacy of radiofrequency ablation in the management of unresectable bile duct and pancreatic cancer: A novel palliation technique. J. Oncol. 2013, 910897. https:\/\/doi.org\/10.1155\/2013\/910897 (2013).","journal-title":"J. Oncol."},{"key":"4297_CR27","doi-asserted-by":"publisher","unstructured":"Liang, H., Peng, Z., Cao, L., Qian, S. & Shao, Z. Metal stenting with or without endobiliary radiofrequency ablation for unresectable extrahepatic cholangiocarcinoma. J. Cancer Ther. 6(11), 12. https:\/\/doi.org\/10.4236\/jct.2015.611106 (2015).","DOI":"10.4236\/jct.2015.611106"},{"key":"4297_CR28","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s00464-020-07689-z","volume":"35","author":"H Kang","year":"2021","unstructured":"Kang, H. et al. Efficacy and safety of palliative endobiliary radiofrequency ablation using a novel temperature-controlled catheter for malignant biliary stricture: A single-center prospective randomized phase II TRIAL. Surg. Endosc. 35, 63\u201373. https:\/\/doi.org\/10.1007\/s00464-020-07689-z (2021).","journal-title":"Surg. Endosc."},{"key":"4297_CR29","doi-asserted-by":"publisher","DOI":"10.1002\/jhbp.960","author":"MX Xia","year":"2021","unstructured":"Xia, M. X. et al. Effect of endoscopic radiofrequency ablation on the survival of patients with inoperable malignant biliary strictures: A large cohort study. J. Hepatobiliary Pancreat. Sci. https:\/\/doi.org\/10.1002\/jhbp.960 (2021).","journal-title":"J. Hepatobiliary Pancreat. Sci."},{"key":"4297_CR30","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1080\/0284186x.2017.1418532","volume":"57","author":"J Dierks","year":"2018","unstructured":"Dierks, J. et al. Translating the ABC-02 trial into daily practice: outcome of palliative treatment in patients with unresectable biliary tract cancer treated with gemcitabine and cisplatin. Acta Oncol 57, 807\u2013812. https:\/\/doi.org\/10.1080\/0284186x.2017.1418532 (2018).","journal-title":"Acta Oncol"},{"key":"4297_CR31","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1111\/1751-2980.12429","volume":"17","author":"X Zheng","year":"2016","unstructured":"Zheng, X. et al. Endoscopic radiofrequency ablation may be preferable in the management of malignant biliary obstruction: A systematic review and meta-analysis. J. Dig. Dis. 17, 716\u2013724. https:\/\/doi.org\/10.1111\/1751-2980.12429 (2016).","journal-title":"J. Dig. Dis."},{"key":"4297_CR32","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1080\/02656736.2020.1763484","volume":"37","author":"G Brandi","year":"2020","unstructured":"Brandi, G. et al. Percutaneous radiofrequency ablation in intrahepatic cholangiocarcinoma: a retrospective single-center experience. Int. J. Hyperth. 37, 479\u2013485. https:\/\/doi.org\/10.1080\/02656736.2020.1763484 (2020).","journal-title":"Int. J. Hyperth."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-04297-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-04297-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-04297-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T15:44:58Z","timestamp":1669304698000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-04297-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,19]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["4297"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-04297-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,19]]},"assertion":[{"value":"4 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Author T.W. has received speaker fees from Boston Scientific, Cook-Medical and Fujifilm. Author M.G. has contributed to advisory boards for Roche, Eisai, MSD and AZ. However, these activities have no potential conflicts of interest with the manuscript. None of the other authors have any potential conflicts (financial, professional or personal) that are relevant to the manuscript.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1011"}}